Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elraglusib in Advanced Solid Tumors
NCT07714395Phase 2Not yet recruiting
- Sponsor
- Actuate Therapeutics
- Start
- Oct 2026
- Primary completion
- Jul 2029
01
Overview
A Phase 2 trial of elraglusib in solid tumor (advanced stage), sponsored by Actuate Therapeutics. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
elraglusib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07714395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07714395.